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ABSTRACT 
Extreme hypertriglyceridemia can lead to acute pancreatitis and rapid lowering of serum 
triglycerides (TG) is necessary in order to prevent such life threatening complication. 
However, there is no established consensus on the acute management of extreme 
hypertriglyceridemia. We retrospectively reviewed ten cases of extreme 
hypertriglyceridemia with mean serum TG on presentation of 101.5±23.4mmol/L 
(8982±2070 mg/dL) managed with insulin. Serum triglyceride decreased by 87±4% in 24 
hours in those patients managed with IV insulin and fasting, and 40±8.4% in those managed 
with IV insulin alone (P = 0.0003). The clinical course was uncomplicated in all except one 
patient who subsequently developed a pancreatic pseudocyst. Thus, combination of IV 
insulin with fasting appears to be an effective, simple and safe treatment strategy in 
immediate management of extreme hypertriglyceridemia. 
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1. INTRODUCTION 
Extreme hypertriglyceridemia (HTG) is associated with risk of acute pancreatitis [1] and 
should be treated promptly. The incidence of HTG-induced pancreatitis (HTGP) accounts for 
approximately 4-10% of all acute pancreatitis cases [1, 2]. It is generally believed that TG 
level of >11.3mmol/L (1000 mg/dL) triggers acute pancreatitis [1]. This threshold, however, 
is arbitrary and a few studies suggested a higher TG level at presentation of around 40-
50mmol/L [2, 3]. 
Both primary (genetic) and secondary disorders of lipoprotein metabolism such as 
diabetes mellitus, obesity, hypothyroidism, excessive alcohol consumption and medications 
can lead to severe HTG [1, 2, 4].  
A variety of treatment modalities including insulin, heparin and plasmapheresis have 
been described in the literature for rapid lowering of serum triglyceride level [1]. However, 
the efficacy and safety of individual modalities have not been well established and there is 
no consensus on the management of extreme HTG (serum TG level ≥50mmol/L) (≥4428 
mg/dL) in the acute setting. Thus, cases with extremely high TG levels present a 
management challenge and the objective of this study is to review acute management and 
clinical course of patients with extreme hypertriglyceridemia. 
 
2. METHODS 
We retrospectively reviewed cases of extreme HTG (serum TG level ≥50mmol/L) (≥4428 
mg/dL) presented to our institution between January 2010 and December 2013. Cases were 
identified from a list of inpatients for which Endocrinology consult was sought. A detailed 
medical records review was conducted to identify baseline epidemiological and clinical 
characteristics of these patients, type and effectiveness of treatment modalities used in 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
acute management of extreme HTG. Ethics approval was obtained from the Institutional 
Human Research Ethics Committee. Contiguous quantitative data were expressed as mean ± 
SD and were compared using two-tailed Student’s t-test. Correlation was assessed by 
Pearson correlation coefficient. P<0.05 was considered statistically significant. 
 
3. RESULTS 
A total of ten patients presented with extreme HTG (serum TG level ≥50mmol/L) 
between January 2010 and December 2013. Half of them (5 out of 10) presented with 
pancreatitis. Mean serum TG level on presentation was 101.5±23.4mmol/L 
(112.9±19.6mmol/L in patients with pancreatitis and 90.2±21.6mmol/L in patients without 
pancreatitis; P = 0.09). The median age of the cohort was 39 years (range 24-55) and nine 
out of 10 patients were men. The group was multi-ethic with majority being Caucasians (6 
out of 10 cases), one Torres Strait Islander (TSI), one Maori origin and two Indians. Mean 
BMI was 31.8±6.5 kg/m
2
. Nine out of 10 cases were patients with type 2 diabetes, three of 
them were newly diagnosed with diabetes on presentation. Four of the 6 patients with 
known diabetes were taking insulin prior to the presentation. Mean HbA1C was 
109±31mmol/mol [12.2±2.8%] and mean blood glucose level on presentation was 
17.4±7mmol/L without evidence of diabetic ketoacidosis or hyperosmolar state. One patient 
without diabetes was thought to have L-asparaginase induced HTG. None of the patients 
had excessive alcohol intake. Family history of dyslipidaemia was reported only by one 
patient. Lipoprotein electrophoresis and Apo lipoprotein E (ApoE) genotype results were 
available for 5 patients. Three patients had Frederickson’s type V and two had type III 
lipoproteinaemia. Four patients were homozygous for ApoE3 and one was heterozygous for 
ApoE3/4. All patients had normal thyroid and renal functions.  
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Nine patients were managed with IV insulin infusion (five of them were also kept fasting, 
four of them had pancreatitis) and one patient (patient 1) was managed with subcutaneous 
basal prandial insulin regimen. Five patients received subcutaneous low dose unfractionated 
heparin 5000 units BD or low molecular weight heparin (enoxaparin 40mg OD) as 
prophylaxis for deep vein thrombosis. Concurrent lipid-lowering agents [supplementary 
table 1] included statin (n=5), fibrate (n=10), omega-3-fish oil (n=4), ezetimibe (n=2), niacin 
(n=1). Five were on statin, two were on fibrate and one was on ezetimibe prior to their 
presentation. All patients received dietary education and low-fat diet was recommended to 
patients who were not fasted. 
Mean serum TG levels decreased by 87±4% in the first 24 hours (from 
105.1±30.1mmol/L to 13.6±4.1mmol/L) in those patients who were managed with IV insulin 
and fasting (Patient 3,4,5,9,10),  40±8.4% in the first 24 hours (from 94.3±18.9mmol/L to 
57.6±16.2mmol/L) in those managed with IV insulin alone (Patient 2,6,7,8) (P = 0.0003) and 
by 23.5% (from 102 to 78mmol/L) in the patient managed with subcutaneous insulin 
(Patient 1). Figure 1 illustrates trends of mean serum TG levels. All patients achieved safe 
serum TG level <11.3mmol/L prior to discharge. Mean nadir serum TG level prior to 
discharge was 6.9±3.7mmol/L. The safe TG level was attained within 2.6±1.8 days in patients 
managed with IV insulin and fasting and within 5.7±1.5 days in patients managed with IV 
insulin alone (P = 0.027).  Table 1 shows detailed trends of serum TG levels in individual 
patients.   
Mean capillary glucose level during first 24 hours on IV insulin infusion was 
11.5±2.5mmol/L and mean insulin infusion rate during first 24 hours was 3.3±1.6 units/hour 
for patients with diabetes. There was a significant positive correlation between the mean 
daily glucose levels and serum TG levels in all patients (r = 0.614, P<0.001). The patients with 
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pancreatitis in our series had uncomplicated clinical courses except one patient (patient 5) 
developing a pancreatic pseudocyst. Six patients returned for follow-up post discharge and 
mean nadir serum TG level on follow-up post-discharge was 3.3±2.2mmol/L. 
 
4. DISCUSSION 
Options for immediate management of extreme HTG include insulin (IV/SC), heparin 
(IV/SC) and/or plasmapheresis [1]. In this study, we found that extreme HTG can be 
managed effectively and safely with IV insulin. A number of case reports have also 
mentioned use of IV insulin in acute management of severe HTG [5-8]. In the largest report 
of 15 patients with less severe degree of HTG (serum triglyceride levels ranged 11-
48mmol/L), the mean reduction in TG by IV insulin infusion within first 24 hours was about 
40% [6]. Our patients had significantly more severe degree of HTG (range: 62.8-143mmol/L) 
at presentation but we found a similar degree of TG lowering by IV insulin infusion alone. 
Moreover, we also found that combination of IV insulin and fasting appears more effective, 
lowering the TG level by about 87% in 24 hours and achieving the safe TG level <11.3mmol/L 
in a shorter time frame.  
Insulin lowers serum triglyceride level by increasing synthesis and action of peripheral 
lipoprotein lipase, thereby improving clearance of TG from the circulation [9]. Fasting 
improves triglyceridemia by reducing the chylomicron formation from the intestine [10].  It 
has been shown that moderate doses (30–50g) of dietary fat dose-dependently increase 
postprandial triglyceridemia [11, 12] and the TG response following a fat-containing meal 
remains elevated for 7–8 hours after the meal even in normolipidemic subjects [13]. Most 
meals contain 20-70g fat. Clinical studies also support that diets rich in highly digestible 
carbohydrate can lead to elevation in serum TG as a result of hepatic VLDL and chylomicron 
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remnants accumulation due to altered lipoprotein secretion and/or clearance [14, 15]. 
Obesity, insulin resistance and type 2 diabetes are known to be associated with exaggerated 
postprandial lipemia [10] and hence exclusion of dietary sources by fasting is expected to 
cause significant improvement of HTG in these patients. 
To our knowledge, the degree of benefit of fasting in the setting of severe 
hypertriglyceridemia has not been reported objectively. In our study, combination of IV 
insulin and fasting appears to be twice as efficient in rapid lowering of serum TG level 
compared to IV insulin alone, indicating that fasting is at least as important as insulin in 
lowering serum TG level. Unfortunately, the degree of TG lowering achievable by fasting 
alone cannot be commented from our study since uncontrolled diabetes in almost all our 
cases necessitated the concomitant use of insulin.  
Studies using plasmapheresis reported about 40-70% reduction of TG after one session 
[16, 17] and 60-80% after several sessions [16-18]. Thus, the degree of the TG lowering 
effect achieved by the combination of IV insulin and fasting approach (87% in 24 hours) is 
higher than that reported to be achievable by plasmapheresis. In addition, the combined 
approach is non-invasive and economical.   
We found that extreme HTG is commonly associated with poorly controlled type 2 
diabetes. This is consistent with previous studies [2, 4], in support of the central role of 
insulin resistance leading to reduced clearance and increased production of TG by the liver 
[19]. Use of insulin infusion in this context has added benefit for management of 
hyperglycemia and we found a positive correlation between the mean daily glucose levels 
and serum TG levels. Use of insulin in management of HTG in the absence of diabetes is 
limited to single case reports [7] and care needs to be taken to avoid hypoglycemia by 
concurrent administration of glucose in that setting.  
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Although the patients in our study were not completely worked up for genetic causes of 
HTG, it is likely that patients with extreme HTG have some form of underlying genetic defect 
in lipoprotein metabolism which manifests clinically on interaction with secondary causes 
such as diabetes, obesity [4, 20].     
Our study is limited by the retrospective nature and relatively small number of cases. 
However, to our knowledge, this represents the largest cohort reported to date of patients 
with extreme hypertriglyceridemia managed with insulin. Given the paucity of literature and 
lack of consensus around management of extreme HTG, we hope that this paper will form a 
basis for conducting larger prospective studies to optimise patient outcomes in the 
immediate management of extreme hypertriglyceridemia. 
 
5. CONCLUSIONS 
Extreme HTG is commonly associated with poorly controlled type 2 diabetes. 
Combination of IV insulin and fasting appears to be a very effective, simple and safe 
treatment strategy in immediate management of extreme HTG. 
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Table 1. Trends of Triglyceride (TG) levels in individual patients 
 
 TG level at 
presentation  
(Day 1) 
(mmol/L)  
TG level  
(Day 2) 
(mmol/L) 
TG level 
(Day 3) 
(mmol/L) 
TG level at 
discharge 
(mmol/L) 
 
Reduction of 
TG level in 
24hr (%) 
 
Time to achieve TG 
<11.3mmol/L 
 
IV insulin+fasting 
(n=5)  
-patient 3 
 
-patient 4 
 
-patient 5 
 
-patient 9 
 
-patient 10 
 
mean±SD  
 
 
 
111.1 
 
96 
 
109.3 
 
146.3 
 
62.8 
 
105.1±30.1  
 
 
18.2 
 
15.9 
 
N/A 
 
10.4 
 
10 
 
13.6±4.1  
 
 
8.5 
 
15.2 
 
N/A 
 
4.7 
 
8 
 
9.1±4.4 
 
 
5.8 
 
10.7 
 
6.5 
 
2.8 
 
2.3 
 
5.6±3.4 
 
 
83.6% 
 
83.4% 
 
N/A 
 
92.9% 
 
84% 
 
87±4% 
 
 
2 Days 
 
5 Days 
 
4 Days 
 
1 Day 
 
1 Day 
 
2.6±1.8 Days 
IV insulin (n=4) 
-patient 2 
 
-patient 6 
 
-patient 7 
 
-patient 8 
 
mean±SD (n=4) 
 
 
96 
 
114.3 
 
98.2 
 
68.8 
 
94.3±18.9  
 
48 
 
80.2 
 
58.2 
 
44.1 
 
57.6±16.2  
 
25.3 
 
55.4 
 
N/A 
 
25.6 
 
35.4±17.3 
 
7.4 
 
11 
 
1.8 
 
10 
 
7.5±4.1 
 
50% 
 
30% 
 
40.7% 
 
35.9% 
 
40±8.4% 
 
7 Days 
 
5 Days 
 
4 Days 
 
7 Days 
 
5.7±1.5 Days 
SC insulin (n=1) 
-patient 1 
 
102 
 
 
78 
 
46.6 
 
11 
 
23.5% 
 
8 days 
Comparing IV 
insulin+fasting Vs 
IV insulin alone 
 
 
P=0.55 
 
P=0.002* 
 
P=0.03* 
 
P=0.46 
 
P=0.0003* 
 
P=0.027* 
 
*denotes statistically significant. Abbreviations: N/A= data not available 
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FIGURE CAPTION 
 
Figure 1: Trends of mean triglyceride levels (Mean reduction of 87% in the first 24h in IV 
insulin+fasting group Vs 40% in IV insulin alone group; P=0.0003) (error bars represent 
standard deviations) 
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Extreme Hypertriglyceridaemia Managed With Insulin  
 
 
Highlights: 
 
• 10 cases of extreme hypertriglyceridemia (mean triglyceride 8982±2070mg/dL) managed by 
insulin. 
• Compared effectiveness of combined fasting and intravenous insulin approach with 
intravenous insulin alone.  
• Extreme hypertriglyceridaemia is commonly associated with type 2 diabetes. 
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Supplementary Table 1: Concurrent lipid lowering agents 
 
 On presentation During hospitalisation and on discharge 
Patient 1 Rosuvastatin 20mg daily Rosuvastatin 20mg daily 
Fenofibrate 145mg daily 
Fish oil 3g daily 
Patient 2 Nil Fenofibrate 145mg daily 
Fish oil 3g twice per day 
Nicotinic acid 500mg tds 
Patient 3 Gemfibrozil 600mg twice per day 
Atorvastatin 80mg daily 
Gemfibrozil 600mg twice per day 
Atorvastatin 80mg daily 
Patient 4 Fenofibrate 145mg daily 
Atorvastatin 80mg daily 
Fenofibrate 145mg daily 
Atorvastatin 80mg daily 
Fish oil 4g twice per day 
Ezetimibe 10mg daily 
Patient 5 Nil Fenofibrate 145mg daily 
Patient 6 Atorvastatin 20mg daily 
Ezetimibe 10mg daily 
Atorvastatin 20mg daily 
Fenofibrate 145mg daily 
Fish oil 2g three times per day 
Ezetimibe 10mg daily 
Patient 7 Nil Fenofibrate 145mg daily 
Patient 8 Atorvastatin 40mg daily Atorvastatin 40mg daily 
Fenofibrate 145mg daily 
Patient 9 Nil Fenofibrate 145mg daily 
Patient 10 Nil Fenofibrate 48mg daily 
 
Fish oil 1g contains 300mg of omega-3 as Eicosapentaenoic acid 180mg and Docosahexaenoic acid 120mg 
 
 
 
